Back to Research

Organization profile

Neurimmune

Neurimmune is a clinical-stage biopharmaceutical company that specializes in the discovery and development of human-derived antibody therapeutics for neurodegenerative and protein aggregation diseases. By utilizing its proprietary Reverse Translational Medicine platform, the company identifies protective immune memories from healthy aged donors to create high-affinity treatments for Alzheimer’s, ALS, and ATTR cardiomyopathy.

Schlieren, SwitzerlandFounded 2006

Overview

1. Executive Summary (Confidence: High)

Neurimmune is a cornerstone of the modern geroscience industry, best known for the discovery of aducanumab, the first FDA-approved treatment targeting amyloid-beta plaques in Alzheimer’s patients.[13] The company’s unique "Reverse Translational Medicine" (RTM) technology platform bypasses traditional drug discovery hurdles by starting with natural human antibodies found in resilient populations.[15] As of early 2024, Neurimmune has strategically regained the global rights to the entire aducanumab portfolio from Biogen, including a high-potential subcutaneous version (NI101SQ) currently in Phase 3.14 With a diversified pipeline targeting cardiovascular (ATTR-CM), CNS (ALS, FTD), and metabolic (Type [2] Diabetes) disorders, Neurimmune leverages deep partnerships with AstraZeneca, Ono Pharmaceutical, and TVM Capital to bring disease-modifying therapies to market.[14]

This is an extract of the full organization profile. To access the full company profile, .

Desktop only

Research is currently available on desktop only.

The Research module is designed for larger screens. Please reopen it on a desktop or laptop to use the screener, filters, detail pages, and admin tools.